Filing Details

Accession Number:
0001567619-21-013733
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-20 18:05:55
Reporting Period:
2021-07-20
Accepted Time:
2021-07-20 18:05:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1623715 Imago Biosciences Inc. IMGO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1070844 A Stephen Schwarzman C/O The Blackstone Group Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1393818 Blackstone Group Inc 345 Park Avenue
New York NY 10154
No No Yes No
1404071 L.l.c. Management Group Blackstone C/O The Blackstone Group Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1464695 L.l.c. Gp I/Ii Holdings Blackstone C/O The Blackstone Group Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1484870 L.p. Ii Holdings Blackstone C/O The Blackstone Group Inc.
345 Park Avenue
New York NY 10154
No No Yes No
1597143 Clarus Lifesciences Iii, L.p. C/O Clarus Ventures, Llc 101 Main Street
Suite 1210
Cambridge MA 02142
No No Yes No
1620148 Clarus Ventures Iii Gp, L.p. C/O Clarus Ventures
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1762202 L.l.c. Iii Clarus Blackstone C/O The Blackstone Group Inc.
345 Park Avenue
New York NY 10154
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-20 1,872,217 $0.00 1,872,217 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 1,155,689 $0.00 3,027,906 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 197,131 $0.00 3,225,037 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 150,000 $16.00 3,375,037 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A convertible Preferred Stock Disposition 2021-07-20 1,872,217 $0.00 1,872,217 $0.00
Common Stock Series B convertible Preferred Stock Disposition 2021-07-20 1,155,689 $0.00 1,155,689 $0.00
Common Stock Series C convertible Preferred Stock Disposition 2021-07-20 197,131 $0.00 197,131 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of the issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) shares of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on July 20, 2021 and had no expiration date.
  2. Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Series II preferred stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
  3. Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
  4. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.